D-0092-2024 Class II Ongoing

Recalled by Glenmark Pharmaceuticals Inc., USA — Mahwah, NJ

FDA drug recall D-0092-2024 was initiated by Glenmark Pharmaceuticals Inc., USA on Oct 23, 2023 and is designated Class II. Reason for recall: Failed Dissolution Specifications: Out of specification for dissolution. The recall status is ongoing. Affected quantity: 16,944 bottles.

Recall details

Product Type
Drugs
Report Date
Nov 15, 2023
Initiation Date
Oct 23, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
16,944 bottles

Product description

Ranolazine Extended-Release Tablets 500mg, 60 Tablets per bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Plot No. 2, Phase-2, Pharma Zone SEZ, Pithampur Dist - Dhar, Madhya Pradesh - 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, NDC 68462-319-60.

Reason for recall

Failed Dissolution Specifications: Out of specification for dissolution.

Distribution pattern

Nationwide

Code information

Lot # 17230388, Exp. 01/31/2025

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0092-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0092-2024. Report a data issue: hello@regdatalab.com.